A 15-Inflammation-Related Gene Signature Predicts the Prognosis of Patients With Pancreatic Ductal Adenocarcinoma

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708.
   PubMed Web of Science ®Google Scholar
• Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. Lancet. 2016;388(10039):73–85. doi:10.1016/S0140-6736(16)00141-0.
   PubMed Web of Science ®Google Scholar
• Sohal DP, Mangu PB, Laheru D. Metastatic pancreatic cancer: American Society Of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2017;13(4):261–264. doi:10.1200/JOP.2016.017368.
   PubMed Web of Science ®Google Scholar
• Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A. The current treatment paradigm for pancreatic ductal adenocarcinoma and barriers to therapeutic efficacy. Front Oncol. 2021;11:688377. doi:10.3389/fonc.2021.688377.
   PubMed Web of Science ®Google Scholar
• Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–327. doi:10.1056/NEJMoa1903387.
   PubMed Web of Science ®Google Scholar
• Chung V, Mansfield AS, Braiteh F, Richards D, Durivage H, Ungerleider RS, et al. Safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors: an open-label, dose escalation, first-in-human, phase I trial. Clin Cancer Res. 2017;23(13):3277–3284. doi:10.1158/1078-0432.CCR-16-2299.
   PubMed Web of Science ®Google Scholar
• Schultze A, Fiedler W. Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase. Anticancer Agents Med Chem. 2011;11(7):593–599. doi:10.2174/187152011796817727.
   PubMed Web of Science ®Google Scholar
• Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med. 2016;22(8):851–860. doi:10.1038/nm.4123.
   PubMed Web of Science ®Google Scholar
• Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 2005;23(23):5281–5293. doi:10.1200/JCO.2005.14.415.
   PubMed Web of Science ®Google Scholar
• Millward M, Price T, Townsend A, Sweeney C, Spencer A, Sukumaran S, et al. Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs. 2012;30(6):2303–2317. doi:10.1007/s10637-011-9766-6.
   PubMed Web of Science ®Google Scholar
• Sun J, Russell CC, Scarlett CJ, McCluskey A. Small molecule inhibitors in pancreatic cancer. RSC Med Chem. 2020;11(2):164–183. doi:10.1039/c9md00447e.
   PubMedGoogle Scholar
• Carbone D, De Franco M, Pecoraro C, et al. Discovery of the 3-amino-1,2,4-triazine-based library as selective PDK1 inhibitors with therapeutic potential in highly aggressive pancreatic ductal adenocarcinoma. Int J Mol Sci. 2023;24(4)
   Web of Science ®Google Scholar
• Kandimalla R, Tomihara H, Banwait JK, Yamamura K, Singh G, Baba H, et al. A 15-gene immune, stromal, and proliferation gene signature that significantly associates with poor survival in patients with pancreatic ductal adenocarcinoma. Clin Cancer Res. 2020;26(14):3641–3648. doi:10.1158/1078-0432.CCR-19-4044.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.025.
   PubMed Web of Science ®Google Scholar
• Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441(7092):431–436. doi:10.1038/nature04870.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15(2):425–430. doi:10.1158/1078-0432.CCR-08-0149.
   PubMed Web of Science ®Google Scholar
• Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010;464(7286):302–305. doi:10.1038/nature08782.
   PubMed Web of Science ®Google Scholar
• Ritter B, Greten FR. Modulating inflammation for cancer therapy. J Exp Med. 2019;216(6):1234–1243. doi:10.1084/jem.20181739.
   PubMed Web of Science ®Google Scholar
• Luo Y, Yang Y, Liu M, Wang D, Wang F, Bi Y, et al. Oncogenic KRAS reduces expression of FGF21 in acinar cells to promote pancreatic tumorigenesis in mice on a high-fat diet. Gastroenterology. 2019;157(5):1413–1428 e1411. doi:10.1053/j.gastro.2019.07.030.
   PubMed Web of Science ®Google Scholar
• Del Poggetto E, Ho I-L, Balestrieri C, Yen E-Y, Zhang S, Citron F, et al. Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science. 2021;373(6561):eabj0486. doi:10.1126/science.abj0486.
   PubMed Web of Science ®Google Scholar
• Sun X, He X, Zhang Y, Hosaka K, Andersson P, Wu J, et al. Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism. Gut. 2022;71(1):129–147. doi:10.1136/gutjnl-2020-322744.
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–1570. doi:10.1126/science.1203486.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Kawada K, Obama K. Inflammation-related biomarkers for the prediction of prognosis in colorectal cancer patients. Int J Mol Sci. 2021;22(15):8002. doi:10.3390/ijms22158002.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Xu D, Song H, Qiu B, Tian D, Li Z, et al. Inflammation and nutrition-based biomarkers in the prognosis of oesophageal cancer: a systematic review and meta-analysis. BMJ Open. 2021;11(9):e048324. doi:10.1136/bmjopen-2020-048324.
   PubMed Web of Science ®Google Scholar
• Gallego A, Mendiola M, Hernando B, Berjon A, Cadiz A, Chaves-Urbano B, et al. Prognostic markers of inflammation in endometrioid and clear cell ovarian cancer. Int J Gynecol Cancer. 2022;32(8):1009–1016. doi:10.1136/ijgc-2022-003353.
   PubMed Web of Science ®Google Scholar
• Ni X-C, Xu J, Yi Y, Fu Y-P, Cai X-Y, Liu G, et al. Inflammation-nutrition score predicts prognosis of patients with resectable hepatocellular carcinoma. Int J Clin Oncol. 2019;24(7):825–835. doi:10.1007/s10147-019-01402-4.
   PubMed Web of Science ®Google Scholar
• Hirahara N, Matsubara T, Kaji S, Hayashi H, Sasaki Y, Kawakami K, et al. Novel inflammation-combined prognostic index to predict survival outcomes in patients with gastric cancer. Oncotarget. 2023;14(1):71–82. doi:10.18632/oncotarget.28353.
   PubMedGoogle Scholar
• Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang T-H, et al. The immune landscape of cancer. Immunity. 2018;48(4):812–830 e814. doi:10.1016/j.immuni.2018.03.023.
   PubMed Web of Science ®Google Scholar
• Cleary JM, Aguirre AJ, Shapiro GI, D'Andrea AD. Biomarker-guided development of DNA repair inhibitors. Mol Cell. 2020;78(6):1070–1085. doi:10.1016/j.molcel.2020.04.035.
   PubMed Web of Science ®Google Scholar
• Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17(8):487–505. doi:10.1038/s41575-020-0300-1.
   PubMed Web of Science ®Google Scholar
• Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154–173. doi:10.1016/j.ccell.2020.10.001.
   PubMed Web of Science ®Google Scholar
• Lawlor RT, Mattiolo P, Mafficini A, Hong S-M, Piredda ML, Taormina SV, et al. Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions. Cancers (Basel). 2021;13(13):3119. doi:10.3390/cancers13133119.
   PubMed Web of Science ®Google Scholar
• Liu S, Harmston N, Glaser TL, Wong Y, Zhong Z, Madan B, et al. Wnt-regulated lncRNA discovery enhanced by in vivo identification and CRISPRi functional validation. Genome Med. 2020;12(1):89. doi:10.1186/s13073-020-00788-5.
   PubMed Web of Science ®Google Scholar
• Cannon A, Thompson CM, Maurer HC, Atri P, Bhatia R, West S, et al. CXCR3 and cognate ligands are associated with immune cell alteration and aggressiveness of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2020;26(22):6051–6063. doi:10.1158/1078-0432.CCR-20-1359.
   PubMed Web of Science ®Google Scholar
• Gao H-F, Cheng C-S, Tang J, Li Y, Chen H, Meng Z-Q, et al. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression. Aging (Albany NY)).). 2020;12(1):502–517. doi:10.18632/aging.102638.
   PubMedGoogle Scholar
• Li X, Li Z, Zhu H, Yu X. Autophagy regulatory genes MET and RIPK2 play a prognostic role in pancreatic ductal adenocarcinoma: a bioinformatic analysis based on GEO and TCGA. Biomed Res Int. 2020;2020:8537381. doi:10.1155/2020/8537381.
   PubMed Web of Science ®Google Scholar
• Wu J, Wang Y, Jiang Z. TNFSF9 is a prognostic biomarker and correlated with immune infiltrates in pancreatic cancer. J Gastrointest Cancer. 2021;52(1):150–159. doi:10.1007/s12029-020-00371-6.
   PubMed Web of Science ®Google Scholar
• Wu D-J, Jiang Y-S, He R-Z, Tao L-Y, Yang M-W, Fu X-L, et al. High expression of WNT7A predicts poor prognosis and promote tumor metastasis in pancreatic ductal adenocarcinoma. Sci Rep. 2018;8(1):15792. doi:10.1038/s41598-018-34094-3.
   PubMedGoogle Scholar
• Huang X, Zhang G, Tang T, Liang T. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development. Mol Cancer. 2021;20(1):44. doi:10.1186/s12943-021-01310-0.
   PubMed Web of Science ®Google Scholar
• Zheng L, Xue J, Jaffee EM, Habtezion A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology. 2013;144(6):1230–1240. doi:10.1053/j.gastro.2012.12.042.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330. doi:10.1038/nature21349.
   PubMed Web of Science ®Google Scholar
• Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–1617. doi:10.1056/NEJMra0901557.
   PubMed Web of Science ®Google Scholar
• Balachandran VP, Beatty GL, Dougan SK. Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology. 2019;156(7):2056–2072. doi:10.1053/j.gastro.2018.12.038.
   PubMed Web of Science ®Google Scholar